Biohaven’s autoimmune drug disappoints investors in study of healthy volunteers 

In a close­ly watched read­out, Bio­haven’s au­toim­mune dis­ease treat­ment led to a 37% re­duc­tion on av­er­age in lev­els of harm­ful an­ti­bod­ies at the high­est re­port­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.